Physician profile
Casey Wilson
NPI 1346917978
$3,376.40
in general payments reported to CMS, 2019-2025
34 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $677 · 2023: $1,089 · 2024: $675 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $356.99 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $217.02 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.78 | 2023-2025 | Xifaxan |
| Pfizer INC. | $192.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $187.91 | 2021-2024 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $168.74 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $156.71 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $154.61 | 2022-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $106.41 | 2022-2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.77 | 2023-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.92 | 2021-2024 | |
| Exact Sciences Corporation | $93.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $92.66 | 2021-2023 | Trintellix |
| Lilly USA, LLC | $91.18 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $90.01 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $54.51 | 2022 | |
| Janssen Pharmaceuticals, INC | $52.59 | 2022 | |
| Ardelyx, INC. | $50.39 | 2024-2025 | Ibsrela |
| Dexcom, INC. | $36.36 | 2022-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $34.16 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $24.31 | 2024 | Voquezna |
| Amgen INC. | $23.37 | 2022 | |
| Mylan Specialty L.P. | $21.72 | 2024 | Yupelri |
| Seqirus USA INC | $19.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.98 | 2021 | |
| Abbott Laboratories | $17.70 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2023 | |
| Axsome Therapeutics, INC. | $14.93 | 2025 | Auvelity |
| Amarin Pharma, INC. | $14.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2023 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $12.11 | 2022 | |
| Genentech USA, INC. | $3.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.